ホームページ 一次抗体 Nav1.7 Antibody [P22E18] For research use only.
Not for use in humans.

Nav1.7 Antibody [P22E18]

Catalog No.: F3300

    Application: Reactivity:
    • Immunohistochemical analysis of formalin fixed paraffin embedded human colorectal cancer tissue with F3300 at 1:200 dilution.
    1/

    当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

    代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

    使用情報

    Dilution
    1:200-1:1000
    Application
    IHC
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    ポジティブコントロール Mouse back skin
    ネガティブコントロール

    プロトコール

    IHC
    Experimental Protocol：
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity

    Nav1.7 Antibody [P22E18] detects endogenous levels of total Nav1.7 protein.
    タンパク質の局在
    細胞膜、細胞突起、細胞内膜系
    Uniprot ID
    Q15858
    Clone
    P22E18
    Synonym(s)
    NENA, SCN9A, Sodium channel protein type 9 subunit alpha, Neuroendocrine sodium channel, Peripheral sodium channel 1, Sodium channel protein type IX subunit alpha, Voltage-gated sodium channel subunit alpha Nav1.7, hNE-Na, PN1
    Background
    NaV1.7 is a voltage-gated sodium channel encoded by the SCN9A gene and is predominantly expressed in peripheral sensory neurons, including small-diameter nociceptive dorsal root ganglion (DRG) neurons, trigeminal ganglion neurons, and sympathetic neurons. Structurally, NaV1.7 consists of a large α-subunit forming the ion-conducting pore, organized into four homologous domains (DI–DIV), each containing six transmembrane segments (S1–S6), with voltage-sensing regions (S4) and a selectivity filter that confers sodium specificity; it may also associate with β-subunits that modulate gating and expression. Functionally, NaV1.7 plays a crucial role in amplifying small, slow depolarizations near resting membrane potential and setting the threshold for action potential initiation, acting as a “threshold channel” in pain-sensing neurons. Gain-of-function mutations in SCN9A cause hyperexcitability of nociceptors, leading to inherited pain syndromes such as inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD), whereas loss-of-function mutations result in congenital insensitivity to pain. Through its low-threshold activation and slow inactivation kinetics, NaV1.7 tightly regulates neuronal excitability and is a major pharmacological target for pain therapeutics.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください
    united states